DK2441777T3 - Polypeptider og antistoffer, som stammer fra kronisk lymfatisk leukæmi-celler, og anvendelser deraf - Google Patents
Polypeptider og antistoffer, som stammer fra kronisk lymfatisk leukæmi-celler, og anvendelser deraf Download PDFInfo
- Publication number
- DK2441777T3 DK2441777T3 DK11009020.6T DK11009020T DK2441777T3 DK 2441777 T3 DK2441777 T3 DK 2441777T3 DK 11009020 T DK11009020 T DK 11009020T DK 2441777 T3 DK2441777 T3 DK 2441777T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- tyr
- ser
- gly
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Claims (10)
1. Isoleret humaniseret anti-CD200-antistof eller CD200- bindende fragment deraf, som omfatter: en letkæde-CDRl med sekvensen ifølge resterne 26-36 ifølge SEQ ID NO: 209; en letkæde-CDR2 med sekvensen ifølge resterne 52-58 ifølge SEQ ID NO: 209; en letkæde-CDR3 med sekvensen ifølge resterne 91-99 ifølge SEQ ID NO: 209; en tungkæde-CDRl med sekvensen ifølge SEQ ID NO: 149; en tungkæde-CDR2 med sekvensen ifølge SEQ ID NO: 174; og en tungkæde-CDR3 med sekvensen ifølge SEQ ID NO: 195.
2. Isoleret humaniseret anti-CD200-antistof eller CD200- bindende fragment deraf, som omfatter: en letkæde-CDRl med sekvensen ifølge resterne 26-36 ifølge SEQ ID NO: 208; en letkæde-CDR2 med sekvensen ifølge resterne 52-58 ifølge SEQ ID NO: 208; en letkæde-CDR3 med sekvensen ifølge resterne 91-99 ifølge SEQ ID NO: 208; en tungkæde-CDRl med sekvensen ifølge SEQ ID NO: 114; en tungkæde-CDR2 med sekvensen ifølge SEQ ID NO: 165; og en tungkæde-CDR3 med sekvensen ifølge SEQ ID NO: 189.
3. Isoleret humaniseret anti-CD200-antistof eller CD200- bindende fragment deraf, som omfatter: en letkæde-CDRl med sekvensen ifølge resterne 26-35 ifølge SEQ ID NO: 207; en letkæde-CDR2 med sekvensen ifølge resterne 51-57 ifølge SEQ ID NO: 207; en letkæde-CDR3 med sekvensen ifølge resterne 90-98 ifølge SEQ ID NO: 207; en tungkæde-CDRl med sekvensen ifølge SEQ ID NO: 111; en tungkæde-CDR2 med sekvensen ifølge SEQ ID NO: 118; og en tungkæde-CDR3 med sekvensen ifølge resterne 100-112 ifølge SEQ ID NO: 201.
4. Isoleret antistof eller CD200-bindende fragment deraf ifølge et hvilket som helst af kravene 1-3, hvor det CD200-bindende fragment er valgt fra gruppen bestående af et Fv-, scFv-, Fab'- eller F(ab')2-fragment.
5. Farmaceutisk sammensætning, som omfatter en farmaceutisk acceptabel bærer og det isolerede antistof eller CD200-bindende fragment ifølge et hvilket som helst af kravene 1-4.
6. Isoleret antistof eller CD200-bindende fragment ifølge et hvilket som helst af kravene 1-4 til anvendelse til behandling af en cancer hos et individ.
7. Isoleret antistof eller CD200-bindende fragment deraf til anvendelse ifølge krav 6, hvor canceren omfatter cancerceller, der overudtrykker CD200.
8. Isoleret antistof eller CD200-bindende fragment deraf til anvendelse ifølge krav 6 eller 7, hvor canceren er kronisk lymfatisk leukæmi.
9. Isoleret antistof eller CD200-bindende fragment deraf til anvendelse ifølge krav 8, hvor den kroniske lymfatiske leukæmi er kronisk lymfatisk B-celleleukæmi.
10. Farmaceutisk sammensætning ifølge krav 5 til anvendelse til behandling af cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/894,672 US9249229B2 (en) | 2000-12-08 | 2004-07-20 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US10/996,316 US7408041B2 (en) | 2000-12-08 | 2004-11-23 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US11/171,567 US20060057651A1 (en) | 2000-12-08 | 2005-06-30 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP05774630A EP1786464A4 (en) | 2004-07-20 | 2005-07-19 | POLYPEPTIDES AND ANTIBODIES FROM CHRONIC LYMPHOCYTIC LEUKEMIC CELLS AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2441777T3 true DK2441777T3 (da) | 2016-05-17 |
Family
ID=35907987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11009020.6T DK2441777T3 (da) | 2004-07-20 | 2005-07-19 | Polypeptider og antistoffer, som stammer fra kronisk lymfatisk leukæmi-celler, og anvendelser deraf |
Country Status (8)
Country | Link |
---|---|
US (4) | US20060057651A1 (da) |
EP (2) | EP1786464A4 (da) |
JP (2) | JP2008513354A (da) |
AU (1) | AU2005274785B2 (da) |
CA (1) | CA2574488C (da) |
DK (1) | DK2441777T3 (da) |
ES (1) | ES2569240T3 (da) |
WO (1) | WO2006020266A2 (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
KR20090107056A (ko) * | 2007-01-11 | 2009-10-12 | 베링거 인겔하임 인터내셔날 게엠베하 | 파골세포의 분화를 통해 골량을 조절하는 cd200 및 이의 수용체 cd200r |
PT3187506T (pt) * | 2007-05-21 | 2019-04-24 | Alderbio Holdings Llc | Anticorpos contra il-6 e sua utilização |
US20110014117A1 (en) * | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
AU2016228280B2 (en) * | 2007-07-12 | 2019-02-21 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
AU2008279619B2 (en) * | 2007-07-25 | 2013-11-14 | Alexion Pharmaceuticals, Inc. | Antibodies to CD200 and uses thereof in inhibiting immune responses |
WO2009121162A1 (en) * | 2008-04-04 | 2009-10-08 | Trillium Therapeutics Inc. | Assay for soluble cd200 |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
CA2745492A1 (en) | 2008-12-08 | 2010-06-17 | Compugen Ltd. | A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
KR20130005264A (ko) * | 2010-01-11 | 2013-01-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-cd200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들 |
BR112012020101A2 (pt) * | 2010-02-11 | 2018-09-25 | Alexion Pharma Inc | método diagnósticos e terapêuticos usando anticorpos anti-cd200. |
EP2616100B1 (en) | 2010-09-17 | 2016-08-31 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
AU2012212066A1 (en) | 2011-02-03 | 2013-08-15 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
KR20120093002A (ko) * | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
CA2837357C (en) | 2011-06-10 | 2020-07-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Anti-ricin antibodies and uses thereof |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
US9382534B2 (en) | 2011-10-05 | 2016-07-05 | Ge Healthcare Dharmacon, Inc. | Optimization of vectors for effective delivery and expression of genetic content |
CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105899537A (zh) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
ES2952064T3 (es) * | 2015-12-16 | 2023-10-26 | Walter & Eliza Hall Inst Medical Res | Inhibición de la proteína SH2 inducida por citocinas en células NK |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
US20190048055A1 (en) * | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
JP7080501B2 (ja) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 医薬品組成物 |
US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
CN109239334A (zh) * | 2018-09-10 | 2019-01-18 | 吉林大学 | 建立时间分辨荧光免疫层析法检测MxA试剂盒 |
CN109633142B (zh) * | 2018-12-22 | 2021-08-27 | 中国人民解放军第四军医大学 | 一种急性髓细胞性白血病诊断模型的建立方法及其应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
DE3307869A1 (de) | 1983-03-05 | 1984-09-06 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe |
EP0335476A3 (en) | 1984-02-08 | 1989-12-13 | Cetus Corporation | Recombinant methods for the production of ricin a, ricin b, ricin or diphtheria toxin (dt)a or ab' fragment, suitable hosts and vectors therefor, and conjugates comprising ricin toxin a chain or diphtheria toxin |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
JPH0246297A (ja) * | 1988-08-08 | 1990-02-15 | Takeda Chem Ind Ltd | モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
US5728815A (en) | 1992-03-30 | 1998-03-17 | Board Of Regents, The University Of Texas System | Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis |
US5508717A (en) | 1992-07-28 | 1996-04-16 | Sony Corporation | Computer pointing device with dynamic sensitivity |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
EP0858506A4 (en) | 1995-10-31 | 2004-12-08 | Uab Research Foundation | GENETIC INDUCTION OF RECEPTORS TO TARGETED RADIOTHERAPY |
WO1997021450A1 (en) | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
PT892643E (pt) | 1996-03-20 | 2002-09-30 | Univ Emory | Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito |
US6011138A (en) | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
PT1032662E (pt) | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | Metodos e composicoes para imunomodulacao. |
US7223729B2 (en) | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
DE19829473C2 (de) * | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020192215A1 (en) | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
AU2001242159B2 (en) | 2000-03-17 | 2006-04-27 | Trillium Therapeutics Inc. | Methods and compositions for immunoregulation |
US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
WO2002011762A2 (en) * | 2000-08-03 | 2002-02-14 | Gorczynski Reginald M | Methods and compositions for modulating tumor growth |
US20030017491A1 (en) | 2000-09-14 | 2003-01-23 | Zuo-Rong Shi | Chromogenic in situ hybridization methods, kits, and compositions |
EP1337560B8 (en) * | 2000-11-22 | 2008-10-15 | Trillium Therapeutics Inc. | Truncated cd200 |
CA2434237C (en) | 2000-12-07 | 2012-05-15 | Eli Lilly And Company | Glp-1 fusion proteins |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
AU2004217434B2 (en) * | 2000-12-08 | 2010-08-26 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP1341902A2 (en) * | 2000-12-08 | 2003-09-10 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US20040198661A1 (en) | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
CA2448668A1 (en) * | 2001-05-24 | 2002-11-28 | Trillium Therapeutics Inc. | Modulation of cd200 receptors |
DE60234369D1 (de) | 2001-09-19 | 2009-12-24 | Alexion Pharma Inc | Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
MXPA05006978A (es) | 2002-12-27 | 2005-08-16 | Schering Corp | Metodos para inducir y mantener la tolerancia inmune. |
EP1606387A4 (en) | 2003-03-04 | 2008-04-23 | Alexion Pharma Inc | VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS |
AU2004257142A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
US6953417B2 (en) * | 2003-11-17 | 2005-10-11 | Borgwarner Inc. | Method for controlling a dual clutch transmission |
JP2007518827A (ja) | 2004-02-02 | 2007-07-12 | シェーリング コーポレイション | Cd200およびcd200rを調節する方法 |
AU2005249540B2 (en) | 2004-06-02 | 2009-02-19 | Sidney Kimmel Cancer Center | Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
JP2009500458A (ja) | 2005-07-11 | 2009-01-08 | マクロジェニクス,インコーポレーテッド | ヒト化抗cd16a抗体を用いる自己免疫疾患の治療方法 |
DK1931709T3 (da) | 2005-10-03 | 2017-03-13 | Xencor Inc | Fc-varianter med optimerede fc-receptorbindingsegenskaber |
RU2520088C2 (ru) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Антитела к ох-2/сd200 и их применение |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
-
2005
- 2005-06-30 US US11/171,567 patent/US20060057651A1/en not_active Abandoned
- 2005-07-19 AU AU2005274785A patent/AU2005274785B2/en not_active Ceased
- 2005-07-19 EP EP05774630A patent/EP1786464A4/en not_active Withdrawn
- 2005-07-19 ES ES11009020.6T patent/ES2569240T3/es active Active
- 2005-07-19 JP JP2007522632A patent/JP2008513354A/ja not_active Withdrawn
- 2005-07-19 WO PCT/US2005/025488 patent/WO2006020266A2/en active Application Filing
- 2005-07-19 EP EP11009020.6A patent/EP2441777B1/en not_active Not-in-force
- 2005-07-19 CA CA2574488A patent/CA2574488C/en not_active Expired - Fee Related
- 2005-07-19 DK DK11009020.6T patent/DK2441777T3/da active
-
2007
- 2007-11-13 US US11/985,322 patent/US7915000B2/en not_active Expired - Fee Related
-
2011
- 2011-03-25 US US13/072,470 patent/US8999328B2/en not_active Expired - Fee Related
-
2012
- 2012-03-09 JP JP2012053212A patent/JP5727406B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-24 US US14/630,262 patent/US20150368341A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1786464A4 (en) | 2009-09-02 |
CA2574488A1 (en) | 2006-02-23 |
AU2005274785A1 (en) | 2006-02-23 |
JP2008513354A (ja) | 2008-05-01 |
US7915000B2 (en) | 2011-03-29 |
US20060057651A1 (en) | 2006-03-16 |
EP2441777A3 (en) | 2012-07-25 |
ES2569240T3 (es) | 2016-05-09 |
US8999328B2 (en) | 2015-04-07 |
JP2012111780A (ja) | 2012-06-14 |
AU2005274785B2 (en) | 2012-05-03 |
WO2006020266A2 (en) | 2006-02-23 |
WO2006020266A3 (en) | 2009-03-12 |
CA2574488C (en) | 2016-11-15 |
EP2441777B1 (en) | 2016-02-17 |
US20150368341A1 (en) | 2015-12-24 |
EP1786464A2 (en) | 2007-05-23 |
EP2441777A2 (en) | 2012-04-18 |
JP5727406B2 (ja) | 2015-06-03 |
US20110236387A1 (en) | 2011-09-29 |
US20090074759A1 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2441777T3 (da) | Polypeptider og antistoffer, som stammer fra kronisk lymfatisk leukæmi-celler, og anvendelser deraf | |
US7408041B2 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
US8840885B2 (en) | Methods for treating chronic lymphocytic leukemia | |
US20040198661A1 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
AU2012211347B9 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
US9249229B2 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
CA2787818C (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
CA2777686A1 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
AU2004217434A1 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |